Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Acceptability
cognitive remediation
drop-out
meta-analysis
schizophrenia
systematic review
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
19
6
2023
pubmed:
9
3
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Acceptability is an important factor for predicting intervention use and potential treatment outcomes in psychosocial interventions. Cognitive remediation (CR) improves cognition and functioning in people with a diagnosis of schizophrenia, but its acceptability, and the impact of participants and treatment characteristics, remain to be investigated. Few studies provide a direct measure of acceptability, but treatment drop-out rates are often available and represent a valid surrogate. The systematic search conducted for the most comprehensive CR outcomes database for schizophrenia was updated in December 2020. Eligible studies were randomized clinical trials comparing CR with any other control condition in patients diagnosed with schizophrenia spectrum disorders and that also reported drop-out in treatment and control arms separately. Acceptability was measured as odd-ratios (OR) of drop-out. Of 2119 identified reports, 151 studies, reporting 169 comparisons between CR and control interventions with 10 477 participants were included in the analyses. The overall rate of drop-out was 16.58% for CR programs and 15.21% for control conditions. In the meta-analysis, no difference emerged between CR interventions and controls [OR 1.10, 95% confidence interval (CI) 0.96-1.25, CR for people diagnosed with schizophrenia is effective and has a good acceptability profile, similar to that of other evidence-based psychosocial interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Acceptability is an important factor for predicting intervention use and potential treatment outcomes in psychosocial interventions. Cognitive remediation (CR) improves cognition and functioning in people with a diagnosis of schizophrenia, but its acceptability, and the impact of participants and treatment characteristics, remain to be investigated. Few studies provide a direct measure of acceptability, but treatment drop-out rates are often available and represent a valid surrogate.
METHOD
METHODS
The systematic search conducted for the most comprehensive CR outcomes database for schizophrenia was updated in December 2020. Eligible studies were randomized clinical trials comparing CR with any other control condition in patients diagnosed with schizophrenia spectrum disorders and that also reported drop-out in treatment and control arms separately. Acceptability was measured as odd-ratios (OR) of drop-out.
RESULTS
RESULTS
Of 2119 identified reports, 151 studies, reporting 169 comparisons between CR and control interventions with 10 477 participants were included in the analyses. The overall rate of drop-out was 16.58% for CR programs and 15.21% for control conditions. In the meta-analysis, no difference emerged between CR interventions and controls [OR 1.10, 95% confidence interval (CI) 0.96-1.25,
CONCLUSIONS
CONCLUSIONS
CR for people diagnosed with schizophrenia is effective and has a good acceptability profile, similar to that of other evidence-based psychosocial interventions.
Identifiants
pubmed: 35257646
doi: 10.1017/S0033291722000319
pii: S0033291722000319
pmc: PMC10277755
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3661-3671Références
Omega. 2020;96:
pubmed: 33746337
Psychiatr Rehabil J. 2018 Dec;41(4):302-311
pubmed: 30010356
Behav Res Methods. 2013 Jun;45(2):576-94
pubmed: 23055166
Schizophr Res. 2019 Jun;208:182-189
pubmed: 30930034
JAMA Psychiatry. 2021 Aug 1;78(8):848-858
pubmed: 33877289
Psychol Med. 2018 Apr;48(5):751-764
pubmed: 28933314
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
Schizophr Bull. 2018 Oct 17;44(6):1254-1266
pubmed: 29300973
Behav Res Ther. 2004 Dec;42(12):1377-401
pubmed: 15500811
Psychol Med. 2014 Oct;44(14):3025-35
pubmed: 25066223
Psychiatr Serv. 1998 Feb;49(2):196-201
pubmed: 9575004
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Clin Psychiatry. 2016 Jun;77(6):799-806
pubmed: 27035157
Schizophr Res. 2021 May;231:154-163
pubmed: 33866260
J Psychiatr Res. 2017 Jul;90:67-77
pubmed: 28231496
Front Psychiatry. 2019 Mar 20;10:147
pubmed: 30949081
Schizophr Bull. 2016 Mar;42(2):327-34
pubmed: 26420905
Schizophr Res. 2020 Jan;215:49-53
pubmed: 31699627
Lancet Psychiatry. 2021 Mar;8(3):191-201
pubmed: 33610228
Schizophr Bull. 2011 Sep;37 Suppl 2:S55-62
pubmed: 21860048
Schizophr Bull. 2020 Apr 10;46(3):496-504
pubmed: 32275756
Biol Psychiatry. 2016 Aug 15;80(4):274-283
pubmed: 26520240
Arch Gen Psychiatry. 2005 Dec;62(12):1305-12
pubmed: 16330718
Eur Neuropsychopharmacol. 2015 Aug;25(8):1178-89
pubmed: 25921551
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Front Psychiatry. 2017 Sep 25;8:177
pubmed: 28993740
J Ment Health. 2016 Jun;25(3):260-6
pubmed: 27045420
Psychol Med. 2020 Jul;50(10):1633-1643
pubmed: 31298171
J Nerv Ment Dis. 2016 Oct;204(10):741-745
pubmed: 27385473
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Psychiatr Serv. 2006 Jan;57(1):139
pubmed: 16399980
Early Interv Psychiatry. 2021 Jun;15(3):457-462
pubmed: 32219993
Schizophr Res Cogn. 2019 May 23;19:100151
pubmed: 31828022
Schizophr Bull. 2015 May;41(3):604-16
pubmed: 25713462
J Affect Disord. 2021 Feb 15;281:264-270
pubmed: 33341008
Res Synth Methods. 2017 Dec;8(4):392-403
pubmed: 28759708
Schizophr Res. 2006 Oct;87(1-3):261-9
pubmed: 16737798
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Schizophr Res. 2010 Aug;121(1-3):266-70
pubmed: 20452749
Schizophr Res. 2020 Apr;218:70-75
pubmed: 32156497
Acta Psychiatr Scand. 2014 Oct;130(4):300-10
pubmed: 24833315
Neurosci Biobehav Rev. 2019 Dec;107:828-845
pubmed: 31557548
Psychol Med. 2021 Apr;51(5):707-715
pubmed: 33860743
Schizophr Bull. 2021 Jul 8;47(4):997-1006
pubmed: 33772310
Psychol Med. 2022 Jun;52(8):1517-1526
pubmed: 32981534
Psychiatr Serv. 2018 Apr 1;69(4):493-494
pubmed: 29607773